» Articles » PMID: 36045746

Transient Receptor Potential Vanilloid Subtype 1: A Potential Therapeutic Target for Fibrotic Diseases

Overview
Journal Front Physiol
Date 2022 Sep 1
PMID 36045746
Authors
Affiliations
Soon will be listed here.
Abstract

The transient receptor potential vanilloid subtype 1 (TRPV1), belonging to the TRPV channel family, is a non-selective, calcium-dependent, cation channel implicated in several pathophysiological processes. Collagen, an extracellular matrix component, can accumulate under pathological conditions and may lead to the destruction of tissue structure, organ dysfunction, and organ failure. Increasing evidence indicates that TRPV1 plays a role in the development and occurrence of fibrotic diseases, including myocardial, renal, pancreatic, and corneal fibrosis. However, the mechanism by which TRPV1 regulates fibrosis remains unclear. This review highlights the comprehensive role played by TRPV1 in regulating pro-fibrotic processes, the potential of TRPV1 as a therapeutic target in fibrotic diseases, as well as the different signaling pathways associated with TRPV1 and fibrosis.

Citing Articles

Multimodal roles of transient receptor potential channel activation in inducing pathological tissue scarification.

Zheng Y, Huang Q, Zhang Y, Geng L, Wang W, Zhang H Front Immunol. 2023; 14:1237992.

PMID: 37705977 PMC: 10497121. DOI: 10.3389/fimmu.2023.1237992.


New Therapeutics for Heart Failure: Focusing on cGMP Signaling.

Mangmool S, Duangrat R, Parichatikanond W, Kurose H Int J Mol Sci. 2023; 24(16).

PMID: 37629047 PMC: 10454066. DOI: 10.3390/ijms241612866.


PDGFβ receptor-targeted delivery of truncated transforming growth factor β receptor type II for improving the in vitro and in vivo anti-renal fibrosis activity via strong inactivation of TGF-β1/Smad signaling pathway.

Wang B, Wang X, Dong Y, Liu X, Xu L, Liu Y Naunyn Schmiedebergs Arch Pharmacol. 2023; 397(1):237-252.

PMID: 37401970 DOI: 10.1007/s00210-023-02594-3.

References
1.
Dees C, Potter S, Zhang Y, Bergmann C, Zhou X, Luber M . TGF-β-induced epigenetic deregulation of SOCS3 facilitates STAT3 signaling to promote fibrosis. J Clin Invest. 2020; 130(5):2347-2363. PMC: 7190914. DOI: 10.1172/JCI122462. View

2.
Okada Y, Shirai K, Miyajima M, Reinach P, Yamanaka O, Sumioka T . Loss of TRPV4 Function Suppresses Inflammatory Fibrosis Induced by Alkali-Burning Mouse Corneas. PLoS One. 2016; 11(12):e0167200. PMC: 5193391. DOI: 10.1371/journal.pone.0167200. View

3.
Otto M, Bucher C, Liu W, Muller M, Schmidt T, Kardell M . 12(S)-HETE mediates diabetes-induced endothelial dysfunction by activating intracellular endothelial cell TRPV1. J Clin Invest. 2020; 130(9):4999-5010. PMC: 7456227. DOI: 10.1172/JCI136621. View

4.
Marshall N, Liang L, Bodkin J, Dessapt-Baradez C, Nandi M, Collot-Teixeira S . A role for TRPV1 in influencing the onset of cardiovascular disease in obesity. Hypertension. 2012; 61(1):246-52. DOI: 10.1161/HYPERTENSIONAHA.112.201434. View

5.
Wang D, Wu Y, Chen Y, Wang A, Lv K, Kong X . Focal selective chemo-ablation of spinal cardiac afferent nerve by resiniferatoxin protects the heart from pressure overload-induced hypertrophy. Biomed Pharmacother. 2018; 109:377-385. DOI: 10.1016/j.biopha.2018.10.156. View